Technology
Health
Pharmaceutical

Jaguar Health

$0.3148
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-11.27%) Today
-$0.04 (-11.27%) Today

Why Robinhood?

You can buy or sell Jaguar Health and other stocks, options, ETFs, and crypto commission-free!

About

Jaguar Health, Inc. engages in the dvelopment of gastrointestinal products for both human prescription use and animals. Its products include Mytesi, Canalevia, Equilevia, and Neonorm. Read More The Mytesi product IS use for relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Canalevia product is intended for treatment of diarrhea in dogs. The Equilevia product is a non-prescription product for gut health in equine athletes. The Neonorm product is a non-prescription animal products. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Employees
36
Headquarters
San Francisco, California
Founded
2013
Market Cap
17.71M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.24M
High Today
$0.43
Low Today
$0.3115
Open Price
$0.4251
Volume
10.56M
52 Week High
$3.53
52 Week Low
$0.115

Collections

Technology
Health
Pharmaceutical
Therapy
Dogs
2015 IPO
US
North America

News

MarketBeatMar 4

Stock Price, News, & Analysis for Jaguar Health

Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical tria...

1,109
Simply Wall StFeb 22

Did You Manage To Avoid Jaguar Health’s Devastating 89% Share Price Drop?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! As every investor would know, you don’t hit a homerun every time you swing. But it would be foolish to simply accept every extremely large loss as an inevitable part of the game. It must have been painful to be a Jaguar Health, Inc. (NASDAQ:JAGX) shareholder over the last year, since the stock price plummeted 89% in that time. A loss like this is a stark reminder that portfolio diversification i...

5,069

Earnings

-$0.76
-$0.52
-$0.29
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.